-
Podoplanin, Human, mAb LpMab17
Podoplanin, Human, mAb LpMab17
- 中文名称：
- Podoplanin, Human, mAb LpMab17
- 英文名称：
- Podoplanin, Human, mAb LpMab17
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA77822
- 规格：
- 0.1 mg|2x0.1 mg|3x0.1 mg|4x0.1 mg|5x0.1 mg
- 保存建议：
- Product should be stored at 4 degree C. Under recommended storage conditions, product is stable for at least one year.
- 货期：
- 6-8周
- 来源宿主：
- Mouse
- 反应种属：
- Human
- 应用：
- WB (Western Blot), IHC (Immunohistochemistry), IF (Immunofluorescence), IA (Immunoassay), FCM/FACS (Flow Cytometry)
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 其他：
克隆性:Monoclonal
同型:Mouse IgG1
克隆号:[LpMab17]
特异性:N/A
纯度:N/A
形式：0.2 ml (100 ug/ml) 0.2 um filtered protein G purified antibody solution in PBS, containing 0.1% bovine serum albumin and 0.02 % sodium azide.
浓度：N/A
- 说明书：
Monoclonal antibody LpMab17 recognizes human Podoplanin (PDPN; agrrus). Podoplanin is a small type_I transmembrane sialoglycoprotein expressed on a broad range of cell types and involved in platelet aggregation and tumor metastasis. The 36 kDa protein was initially identified as a biomarker of lympatic endothelium, alveolar epithelium and glomerular podocytes. Expression has also been found in many tumors. However the functional role of PDPN is still poorly understood. Podoplanin consists of an extracellular domain, transmembrane domain and a cytoplasmic tail. In its extracellular domain it possesses a platelet aggregation stimulating (PLAG) domain. Podoplanin has got three PLAG domains of which PLAG3 is critical for binding with C-type lectin receptor-2 (CLEC-2). This PDPN specific receptor mediates platelet aggregation. This interaction is required to initiate and maintain separation of blood and lymphatic vessels and can be critical in process of cancer metastasis. This may lead to PDPN as possible therapeutic target. Antibody LpMab-17 recognizes a non-PLAg domain (Gly77-Asp82). Although PDPN is quite conserved between species, LpMab17 does not bind monkey PDPN.
